SB 242784

Drug Profile

SB 242784

Latest Information Update: 19 Aug 2005

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SmithKline Beecham Biologicals
  • Developer NiKem Research; SmithKline Beecham Biologicals
  • Class Indoles; Osteoporosis therapies; Piperidines
  • Mechanism of Action Bone resorption factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Postmenopausal osteoporosis

Most Recent Events

  • 19 Aug 2005 Discontinued - Preclinical for Postmenopausal osteoporosis in Europe (unspecified route)
  • 20 Feb 2003 A preclinical study has been added to the Musculoskeletal pharmacodynamics section
  • 04 Dec 2002 Preclinical trials in Postmenopausal osteoporosis in Europe (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top